Search
Research
Optimization is required when using linked hospital and laboratory data to investigate respiratory infectionsChart review to validate linked microbiological data
Research
Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancerThe trivalent inactivated influenza vaccine is safe, immunogenic, provides clinical protection and should be administered annually to immunosuppressed children receiving treatment for cancer
Research
Duplex quantitative PCR assay for detection of haemophilus influenzae that distinguishes fucose-and protein d-negative strainsDeveloped a specific Haemophilus influenzae quantitative PCR (qPCR) that also identifies fucose-negative and protein D-negative strains
Research
Development of a human papillomavirus vaccination intervention for Australian adolescentsIntervention to address young people's low levels of understanding, to promote their involvement in consent and reduce vaccination-related fear and anxiety.
Research
Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012-2014: The FluMum studyWe assessed the safety of receiving an influenza vaccination during any trimester of pregnancy with respect to preterm births and infant birthweight.
Research
Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenzaThese findings reinforce current recommendations for annual influenza vaccination, particularly those at greatest risk of influenza disease.
Research
FluMum: A prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in revention of influenzaEvidence is emerging of benefit to the infant with respect to preventing influenza infection in the first 6 months of life. The FluMum study aims to...
Research
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccineThe efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with HPV...
Research
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisNirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.